-+ 0.00%
-+ 0.00%
-+ 0.00%

According to a report published by Citigroup, the US Food and Drug Administration issued a full response letter on advanced non-small cell lung cancer after treatment with Kang Fang Biotech's IvonesCimab in combination with EGFR-TKI, believing that Harmoni did not establish sufficient clinical evidence, and that the benefit from a statistically significant progression-free survival period was not accompanied by a statistically significant improvement in overall survival. The bank believes that the HarmonI results may be related to factors such as study design; since CRL is efficacy related, there is limited room for re-submission, and the focus is on other global phase III studies that may provide more clear OS evidence. Among them, HarmonI-3 is the next important catalyst to pay close attention to. The bank indicated that the FDA's decision would delay potential overseas concession revenue and reduce ivonescimab's near-term visibility for commercialization in the US. As a result, the bank lowered its revenue forecast for the 2027 and 2028 fiscal years by 1% and its net profit forecast by 12% and 3% respectively. The target price was lowered from HK$171 to HK$163, maintaining a “buy” rating.

Zhitongcaijing·11/16/2026 07:49:05
Listen to the news
According to a report published by Citigroup, the US Food and Drug Administration issued a full response letter on advanced non-small cell lung cancer after treatment with Kang Fang Biotech's IvonesCimab in combination with EGFR-TKI, believing that Harmoni did not establish sufficient clinical evidence, and that the benefit from a statistically significant progression-free survival period was not accompanied by a statistically significant improvement in overall survival. The bank believes that the HarmonI results may be related to factors such as study design; since CRL is efficacy related, there is limited room for re-submission, and the focus is on other global phase III studies that may provide more clear OS evidence. Among them, HarmonI-3 is the next important catalyst to pay close attention to. The bank indicated that the FDA's decision would delay potential overseas concession revenue and reduce ivonescimab's near-term visibility for commercialization in the US. As a result, the bank lowered its revenue forecast for the 2027 and 2028 fiscal years by 1% and its net profit forecast by 12% and 3% respectively. The target price was lowered from HK$171 to HK$163, maintaining a “buy” rating.